PROTEOME SCIENCES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.51 GBX | +0.29% |
|
+15.08% | -22.52% |
| Apr. 10 | Proteome Sciences shares drop as revenue plunges and swings to loss | AN |
| Apr. 10 | Proteome Sciences plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 7.78M 9.73M | Sales 2023 | 5.03M 6.29M | Capitalization | 13.37M 16.72M |
|---|---|---|---|---|---|
| Net income 2022 | 1M 1.25M | Net income 2023 | -2M -2.5M | EV / Sales 2022 | 2.35 x |
| Net Debt 2022 | 7.92M 9.9M | Net Debt 2023 | 11.45M 14.31M | EV / Sales 2023 | 4.94 x |
| P/E ratio 2022 |
8.14
x | P/E ratio 2023 |
-5.46
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.76% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.29% | ||
| 1 week | +15.08% | ||
| Current month | +3.54% | ||
| 1 month | +0.57% | ||
| 3 months | -19.31% | ||
| 6 months | -40.51% | ||
| Current year | -22.52% |
1 week
2.98
4.00
1 month
2.654.00
Current year
2.655.75
1 year
2.658.79
3 years
2.6510.00
5 years
2.2510.00
10 years
2.2043.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mariola Söhngen
CEO | Chief Executive Officer | 63 | 20-09-14 |
Abdelghani Omari
DFI | Director of Finance/CFO | 48 | 22-08-31 |
| Chairman | 71 | 93-12-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 93-12-09 | |
Roger McDowell
BRD | Director/Board Member | 69 | 14-06-30 |
Ursula Ney
BRD | Director/Board Member | 72 | 17-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 3.51 | +0.29% | 412 |
| 24-04-24 | 3.5 | +7.69% | 0 |
| 24-04-23 | 3.25 | 0.00% | 0 |
| 24-04-22 | 3.25 | -1.52% | 500 |
| 24-04-19 | 3.3 | +8.20% | 0 |
Delayed Quote London S.E., April 25, 2024 at 11:35 am EDT
More quotes
Proteome Sciences plc is a specialist provider of contract proteomics services. The services enable drug discovery, development, and biomarker identification and employ workflows for the optimum analysis of tissues, cells, and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic, and therapeutic applications. SysQuant and TMT MS2 are its unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using super-depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents, which are sold for multiplex quantitative proteomics.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -22.52% | 12.84M | |
| -2.92% | 185B | |
| -3.80% | 107B | |
| -5.48% | 67.55B | |
| +11.22% | 54.6B | |
| +16.74% | 47.42B | |
| +2.33% | 42.24B | |
| +4.56% | 28.24B | |
| +1.64% | 26.42B | |
| +11.27% | 25.66B |
- Stock Market
- Equities
- PRM Stock
